Evidence map›Paper›PMID 29507628›Full record

ArticleTheranostics2018

Longitudinal Multiplexed Measurement of Quantitative Proteomic Signatures in Mouse Lymphoma Models Using Magneto-Nanosensors.

Jung-Rok Lee, Iris Appelmann, Cornelius Miething, Tyler O Shultz, Daniel Ruderman, Dokyoon Kim, Parag Mallick, Scott W Lowe, Shan X Wang

Abstract read
In one paragraph

Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jung-Rok LeeDivision of Mechanical and Biomedical Engineering, Ewha Womans University, Seoul, South Korea.
Iris AppelmannCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Cornelius MiethingCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Tyler O ShultzDepartment of Materials Science and Engineering, Stanford University, Stanford, California, USA.
Daniel RudermanEllison Institute of Transformative Medicine of USC, USC Keck School of Medicine, Los Angeles, California, USA.
Dokyoon KimDepartment of Materials Science and Engineering, Stanford University, Stanford, California, USA.
Parag MallickDepartment of Medicine, Department of Radiology, Stanford University, Stanford, California, USA.
Scott W LoweCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Shan X WangDepartment of Materials Science and Engineering, Stanford University, Stanford, California, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
Scientific ReagentsP01CA087497 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI PRIVES, CAROL · 2000 to 2021
$35.4M
TRANS-NETWORK PROJECTSU54CA143907 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI NOLAN, GARRY P · 2009 to 2013
$15.2M
Pilot ProjectsU54CA151459 · NCI · STANFORD UNIVERSITY · PI GAMBHIR, SANJIV S · 2010 to 2014
$12.6M
MSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9M
Nano Characterization and Nano Fabrication CoreU54CA199075 · NCI · STANFORD UNIVERSITY · PI GAMBHIR, SANJIV S · 2015 to 2019
$9.6M
NCI NIH HHS P01 CA087497NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016359NCI NIH HHS U54 CA143907NCI NIH HHS U54 CA151459NCI NIH HHS U54 CA199075NIH HHS U54 OD020355
6 · The paper itself

Abstract

Cancer proteomics is the manifestation of relevant biological processes in cancer development. Thus, it reflects the activities of tumor cells, host-tumor interactions, and systemic responses to cancer therapy. To understand the causal effects of tumorigenesis or therapeutic intervention, longitudinal studies are greatly needed. However, most of the conventional mouse experiments are unlikely to accommodate frequent collection of serum samples with a large enough volume for multiple protein assays towards single-object analysis. Here, we present a technique based on magneto-nanosensors to longitudinally monitor the protein profiles in individual mice of lymphoma models using a small volume of a sample for multiplex assays.

Indexed as

ProteomicsAnimalsCytokinesDisease Models, AnimalLymphomaMagneticsMice, Inbred C57BLMice, KnockoutNanotechnologySurvival AnalysisUp-RegulationCytokinesIL-6longitudinal studymagneto-nanosensorsmouse lymphomaProteomic signaturetherapeutic intervention

Identifiers

PMID29507628
PMCPMC5835944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.